1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
February 2026 in “Medicina” Hyaluronic Acid Profhilo® reduces skin inflammation and nerve-related pain in atopic dermatitis.
January 2025 in “Fìzìologìčnij žurnal” PDRN may reduce inflammation and complications in revision rhinoplasty for patients with high fibrinogen levels.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
24 citations
,
January 1996 in “The Prostate” Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
1 citations
,
June 2022 in “Current drug safety” Topical minoxidil can rarely cause pleural effusion if ingested.
6 citations
,
August 2021 in “International Journal of Pharmaceutics” A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
April 2018 in “Journal of Investigative Dermatology” February 2025 in “Actas Dermo-Sifiliográficas” Low-dose oral minoxidil can help improve hair and eyebrow growth in people with frontal fibrosing alopecia.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
86 citations
,
July 2012 in “British journal of dermatology/British journal of dermatology, Supplement” There may be a connection between Frontal Fibrosing Alopecia and Lichen Planus Pigmentosus, and more research is needed to confirm this.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
108 citations
,
November 1980 in “British Journal of Dermatology” Oral retinoids are effective for various skin conditions but have side effects and should not be used during pregnancy.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
31 citations
,
September 2014 in “International Journal of Dermatology” Anthralin is effective for psoriasis and alopecia with minimal systemic side effects but can irritate the skin.
14 citations
,
March 2007 in “Pediatric pulmonology” Inhaled steroids in children may cause excessive hair growth and not always go away after stopping the medication.
2 citations
,
April 2024 in “Journal of International Medical Research” Secukinumab and acitretin together may quickly and effectively treat severe generalized pustular psoriasis.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
January 2023 in “Figshare” Triple therapy with clobetasol, hydroxychloroquine, and N-acetylcysteine is recommended for better outcomes in treating lichen planopilaris.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
1 citations
,
January 2020 Resveratrol-loaded nanoparticles show promise for lung cancer treatment.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
Many patients in the rheumatology clinic adjusted or stopped their medications due to side effects.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly”